相关实验视频

Updated: Jun 1, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

BMP6参与了参与APAP肝毒性的分子机制

Patricia Marañón¹, Stephania C Isaza², Esther Rey²

¹Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria Princesa (IIS-P), Madrid, Spain. patmaranon@gmail.com.

Archives of toxicology

|January 19, 2025

概括

骨形态遗传蛋白6 (BMP6) 显示出作为乙氨基 (APAP) 诱导的急性肝衰竭 (ALF) 的生物标志物具有前景. 增加的BMP6水平与肝损伤严重程度相关,并且可能在APAP毒性期间在肝细胞-巨细胞通信中发挥作用.

科学领域:

肝病学肝病学是一种肝病学.
生物标志物发现发现
毒理学毒理学毒理学

背景情况:

乙氨基 (APAP) 诱导的急性肝衰竭 (ALF) 缺乏准确的诊断方法,需要新的生物标志物.
骨形态遗传蛋白6 (BMP6) 正在研究其在APAP诱导的肝损伤中的潜在作用.

研究的目的:

评估BMP6在APAP诱导的ALF进展中的作用.
评估BMP6作为ALF诊断生物标志物的潜力.
为了调查BMP6在APAP毒性期间的肝细胞-巨细胞交叉的参与.

主要方法:

评估了APAP治疗小鼠和APAP过量服用患者的人类血清样本中的肝脏和循环BMP6表达.
在APAP暴露后的肝细胞中评估了BMP6的表达和释放.
在Huh7细胞中利用了BMP6基因沉默,并评估了对THP1单细胞的膜效应.

主要成果:

肝脏和血清BMP6水平在患有APAP诱导ALF的小鼠中升高.
在APAP过量服用患者中,循环中的BMP6与ALT活性呈正相关性.
接受APAP治疗的肝细胞释放BMP6,影响单细胞标记体的表达,这表明肝细胞-巨细胞交叉的作用.

结论:

肝脏BMP6表达在APAP诱导的急性肝损伤中增加,表明其作为肝损伤严重程度的生物标志物的潜力.
在APAP诱导的肝毒性中,BMP6可能会调解肝细胞和巨细胞之间的交叉声.
需要进一步研究BMP6作为ALF的诊断和预后工具.

关键词:

阿尔夫,阿尔夫,阿尔夫,阿尔夫在 APAP APAP 中.BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 BMP6 生物标志物生物标志物骨形态遗传蛋白质是一种骨形态遗传蛋白质.

更多相关视频

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...